The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Lombardo, D., & Kiselev, M. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030543 · Cited by 718
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Biodegradable Polymeric Nanoparticles for Drug Delivery to Solid Tumors
Gagliardi, A., Giuliano, E., Venkateswararao, E., Fresta, M., Bulotta, S., Awasthi, V., & Cosco, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.601626 · Cited by 571
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Self-citationShi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine
Ju, Y., Lee, W. S., Pilkington, E. H., Kelly, H. G., Li, S., Selva, K. J., Wragg, K. M., Subbarao, K., Nguyen, T. H. O., Rowntree, L. C., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04543 · Cited by 372
Self-citationPolymeric Delivery of Therapeutic Nucleic Acids
Kumar, R., Santa Chalarca, C. F., Bockman, M. R., Bruggen, C. V., Grimme, C. J., Dalal, R. J., Hanson, M. G., Hexum, J. K., & Reineke, T. M. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00997 · Cited by 365
Antimicrobial nanoparticles: current landscape and future challenges
Mondal, S. K., Chakraborty, S., Manna, S., & Mandal, S. M. (2024) · RSC Pharmaceutics · doi:10.1039/d4pm00032c · Cited by 318
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases
Pilkington, E. H., Suys, E. J. A., Trevaskis, N. L., Wheatley, A. K., Zukancic, D., Algarni, A., Al-Wassiti, H., Davis, T. P., Pouton, C. W., Kent, S. J., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.023 · Cited by 260
Self-citationFrontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
PEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 233
Lombardo, D., Calandra, P., Pasqua, L., & Magazù, S. (2020) · Materials · doi:10.3390/ma13051048 · Cited by 229
Jeong, M., Lee, Y., Park, J., Jung, H., & Lee, H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114990 · Cited by 220
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Gagliardi, M., & Ashizawa, A. T. (2021) · Biomedicines · doi:10.3390/biomedicines9040433 · Cited by 210
“Alternatives to PEGylation currently being explored include poly(glycerols), poly(oxazolines), and poly(zwitterions) [110,113].”
BackgroundInfluentialPolymeric delivery systems for nucleic acid therapeutics: Approaching the clinic
van den Berg, A. I. S., Yun, C.-O., Schiffelers, R. M., & Hennink, W. E. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.014 · Cited by 208
Toward Green Atom Transfer Radical Polymerization: Current Status and Future Challenges
Dworakowska, S., Lorandi, F., Gorczyński, A., & Matyjaszewski, K. (2022) · Advanced Science · doi:10.1002/advs.202106076 · Cited by 210
Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement
Estapé Senti, M., de Jongh, C. A., Dijkxhoorn, K., Verhoef, J. J. F., Szebeni, J., Storm, G., Hack, C. E., Schiffelers, R. M., Fens, M. H., & Boross, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.042 · Cited by 196
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
Ju, Y., Carreño, J. M., Simon, V., Dawson, K., Krammer, F., & Kent, S. J. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00825-x · Cited by 201
Recent advances in long-acting drug delivery systems for anticancer drug
Pacheco, C., Baião, A., Ding, T., Cui, W., & Sarmento, B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114724 · Cited by 190
Strategies for the development of metalloimmunotherapies
Sun, X., Zhou, X., Shi, X., Abed, O. A., An, X., Lei, Y. L., & Moon, J. J. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01221-7 · Cited by 163
“However, because PEGylated drugs can lead to the formation of anti-PEG antibodies 206 , alternative polymers are under development 207 .”
Szebeni, J., Storm, G., Ljubimova, J. Y., Castells, M., Phillips, E. J., Turjeman, K., Barenholz, Y., Crommelin, D. J. A., & Dobrovolskaia, M. A. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01071-x · Cited by 165
Chen, X., Argandona, S. M., Melle, F., Rampal, N., & Fairen‐Jiménez, D. (2023) · Chem · doi:10.1016/j.chempr.2023.09.016 · Cited by 189
Jain, S., Venkataraman, A. K., Wechsler, M. E., & Peppas, N. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114000 · Cited by 189
PEGYLATION: an important approach for novel drug delivery system
Yadav, D., & Dewangan, H. K. (2020) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2020.1825304 · Cited by 178
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Recent Advances in the Surface Functionalization of PLGA-Based Nanomedicines
El‐Hammadi, M. M., & Arias, J. L. (2022) · Nanomaterials · doi:10.3390/nano12030354 · Cited by 172
The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects
Lu, B., Lim, J. M., Yu, B., Song, S., Neeli, P. K., Sobhani, N., Pavithra, K., Bonam, S. R., Kurapati, R., Zheng, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1332939 · Cited by 194
Shi, Y., Lu, A., Wang, X., Belhadj, Z., Wang, J., & Zhang, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.002 · Cited by 158
Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers
Brenner, J. S., Mitragotri, S., & Muzykantov, V. R. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-121219-024239 · Cited by 134
Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
Lee, J., Woodruff, M. C., Kim, E. H., & Nam, J. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00999-x · Cited by 149
Self-citationRecent developments in the use of gold and silver nanoparticles in biomedicine
Pasparakis, G. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1817 · Cited by 141
“…polyethylene glycol (PEG) is the polymer of choice for Au NP passivation (although there exist plentiful alternatives; Barz et al., 2011; Thi et al., 2020), which can be combined with additional thiol-functionalized targeting ligands, imaging probes, or even drug/biologic molecules to…”
BackgroundAbdulsalam, L., Abubakar, S., Permatasari, I., Lawal, A. A., Uddin, S., Ullah, S., & Ahmad, I. (2025) · Polymers · doi:10.3390/polym17212901 · Cited by 157
Moayedi, S., Xia, W., Lundergan, L., Yuan, H., & Xu, J. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c02664 · Cited by 139
Endocytosis and Organelle Targeting of Nanomedicines in Cancer Therapy
Wang, X., Qiu, Y., Wang, M., Zhang, C.-H., Zhang, T., Zhou, H., Zhao, W., Zhao, W., Xia, G., & Shao, R. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s274289 · Cited by 135
Challenge to overcome current limitations of cell-penetrating peptides
Kim, G. C., Cheon, D. H., & Lee, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2021.140604 · Cited by 140
Szczęch, M., & Szczepanowicz, K. (2020) · Nanomaterials · doi:10.3390/nano10030496 · Cited by 132
Targeting the blood-brain barrier for the delivery of stroke therapies
D'Souza, A., Dave, K. M., Stetler, R. A., & S. Manickam, D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.015 · Cited by 122
Polymersome-based protein drug delivery – quo vadis?
Gouveia, M. G., Wesseler, J. P., Ramaekers, J., Weder, C., Scholten, P. B. V., & Bruns, N. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00106c · Cited by 120
The Art of PEGylation: From Simple Polymer to Sophisticated Drug Delivery System
Makharadze, D., del Valle, L. J., Katsarava, R. D., & Puiggalí, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073102 · Cited by 135
Developments in nanotechnology approaches for the treatment of solid tumors
Venturini, J., Chakraborty, A., Baysal, M. A., & Tsimberidou, A. M. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00656-1 · Cited by 130
“However, anti-PEG antibodies can accelerate nanoparticle clearance, reducing efficacy [197, 198].”
Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress
Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 131
Anti-PEG antibodies: Current situation and countermeasures
Fu, J., Wu, E., Li, G., Wang, B., & Zhan, C. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102163 · Cited by 122
Polyethylene glycol immunogenicity in nanomedicine
Chen, Y., Su, Y.-C., & Roffler, S. R. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00321-6 · Cited by 113
Yu, L., Li, K., Zhang, J., Jin, H., Saleem, A., Song, Q., Jia, Q., & Li, P. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01132 · Cited by 114
Haghighi, E., Abolmaali, S. S., Dehshahri, A., Shaegh, S. A. M., Azarpira, N., & Tamaddon, A. M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02972-w · Cited by 130
Mahmoud, K. Y., Swidan, S. A., El-Nabarawi, M. A., & Teaima, M. H. M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01309-9 · Cited by 112
Polyoxazoline: A review article from polymerization to smart behaviors and biomedical applications
Mahand, S. N., Aliakbarzadeh, S., Moghaddam, A., Moghaddam, A. S., Kruppke, B., Nasrollahzadeh, M., & Khonakdar, H. A. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111484 · Cited by 117
The future of poly(2-oxazoline)s
Hoogenboom, R. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111521 · Cited by 113
Fu, S., Zhu, X., Fanghua, H., & Chen, X. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081074 · Cited by 125
Sheffey, V. V., Siew, E. B., Tanner, E. E. L., & Eniola‐Adefeso, O. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101536 · Cited by 106
Glassman, P. M., Hood, E. D., Ferguson, L. T., Zhao, Z., Siegel, D. L., Mitragotri, S., Brenner, J. S., & Muzykantov, V. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113992 · Cited by 107
Unravelling Surface Modification Strategies for Preventing Medical Device‐Induced Thrombosis
Luu, C. H., Nguyen, N., & Ta, H. T. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301039 · Cited by 108
Bio-Applications of Multifunctional Melanin Nanoparticles: From Nanomedicine to Nanocosmetics
Mavridi‐Printezi, A., Guernelli, M., Menichetti, A., & Montalti, M. (2020) · Nanomaterials · doi:10.3390/nano10112276 · Cited by 103
Peptide Drug Conjugates and Their Role in Cancer Therapy
Heh, E., Allen, J. C., Ramirez, F., Lovasz, D., Fernandez, L., Hogg, T., Riva, H. R., Holland, N. A., & Chacon, J. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010829 · Cited by 107
Nguyen, D. H., Lee, J. S., Park, K. H., Ching, Y. C., Nguyen, X., Phan, V. H. G., & Thi, T. T. H. (2020) · Nanomaterials · doi:10.3390/nano10030542 · Cited by 94
“Moreover, capping agents using synthetic polymers have been become unfavorable, due to cumulative risks in humans, leading to create anti-polymer antibodies, further causing accelerated blood clearance of some pharmaceutical products [16].”
BackgroundSelf-citationOral peptide delivery: challenges and the way ahead
Dubey, S. K., Parab, S., Dabholkar, N., Agrawal, M., Singhvi, G., Alexander, A., Bapat, R. A., & Kesharwani, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.001 · Cited by 101
Zhang, C., Ma, Y., Zhang, J., Kuo, J. C., Zhang, Z., Xie, H., Zhu, J., & Liu, T. (2022) · Molecules · doi:10.3390/molecules27061943 · Cited by 108
“However, PEG also faces several challenges, such as decreased drug activity and immunogenicity induction [217].”
BackgroundAlgarni, A., Pilkington, E. H., Suys, E. J. A., Al-Wassiti, H. A., Pouton, C. W., & Truong, N. P. (2022) · Biomaterials Science · doi:10.1039/d2bm00168c · Cited by 97
Self-citationPelosi, C., Tinè, M. R., & Wurm, F. R. (2020) · European Polymer Journal · doi:10.1016/j.eurpolymj.2020.110079 · Cited by 98
“the polymer accumulation and the development of anti-PEG antibodies and hypersensitivity reactions, see Section 2) have been reported, increasing the interest of research on novel polymers leading to a stealth effect [25,39].”
BackgroundSoroudi, S., Jaafari, M. R., & Arabi, L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.023 · Cited by 102
Liposomal Formulations: A Recent Update
Agrawal, S. S., Baliga, V., & Londhe, V. Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010036 · Cited by 106
Comparison of extracellular vesicle isolation processes for therapeutic applications
Williams, S., Fernández‐Rhodes, M., Law, A., Peacock, B., Lewis, M. P., & Davies, O. G. (2023) · Journal of Tissue Engineering · doi:10.1177/20417314231174609 · Cited by 104
Friedl, J. D., Nele, V., Rosa, G. D., & Bernkop‐Schnürch, A. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202103347 · Cited by 95
Liang, G., Cao, W., Tang, D., Zhang, H., Yu, Y., Ding, J., Karges, J., & Xiao, H. (2024) · ACS Nano · doi:10.1021/acsnano.3c11154 · Cited by 89
A comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 105
Vu, M. N., Kelly, H. G., Wheatley, A. K., Peng, S., Pilkington, E. H., Veldhuis, N. A., Davis, T. P., Kent, S. J., & Truong, N. P. (2020) · Small · doi:10.1002/smll.202002861 · Cited by 90
Self-citationWeng, W., Meng, T., Zhao, Q., Shen, Y., Fu, G., Shi, J., Zhang, Y., Wang, Z., Wang, M., Pan, R., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1368 · Cited by 97
Sanchez, A. J. D. S., Loughrey, D., Echeverri, E. S., Huayamares, S. G., Radmand, A., Paunovska, K., Hatit, M. Z. C., Tiegreen, K. E., Santangelo, P. J., & Dahlman, J. E. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304033 · Cited by 90
Zukancic, D., Suys, E. J. A., Pilkington, E. H., Algarni, A., Al-Wassiti, H. A., & Truong, N. P. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111068 · Cited by 83
“Although PEGylated drugs and nanoparticles may cause PEG immunogenicity and accelerated blood clearance (ABC) (see our review for more details) [26], there is still a long list of PEGylated drugs and nanoparticles approved for clinical treatments including Onpattro®, the first and only FDA-approved LNPs used for gene…”
BackgroundSelf-citationStriving for Uniformity: A Review on Advances and Challenges To Achieve Uniform Polyethylene Glycol
Bento, C., Katz, M., Santos, M. M. M., & Afonso, C. A. M. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00428 · Cited by 89
Melnyk, T., Đorđević, S., Conejos‐Sánchez, I., & Vicent, M. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.007 · Cited by 86
Multi-targeted 1H/19F MRI unmasks specific danger patterns for emerging cardiovascular disorders
Flögel, U., Temme, S., Jacoby, C., Oerther, T., Keul, P., Flocke, V., Wang, X., Bönner, F., Nienhaus, F., Peter, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26146-6 · Cited by 83
Chemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications
Braatz, D., Cherri, M., Tully, M., Dimde, M., Ma, G., Mohammadifar, E., Reisbeck, F., Ahmadi, V., Schirner, M., & Haag, R. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203942 · Cited by 80
Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies
Haddad, H. F., Burke, J. A., Scott, E. A., & Ameer, G. A. (2021) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-021-00198-y · Cited by 86
Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
Kim, M., Hwang, Y., Lim, S., Jang, H., & Kim, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091197 · Cited by 88
“This modification extends the circulation time in the bloodstream and enhances stability, biocompatibility, and biodegradability [57].”
BackgroundFrom Nature to Innovation: The Uncharted Potential of Natural Deep Eutectic Solvents
Schuh, L., Reginato, M., de Souza, I. F., Falcao, L., Boron, L., Gris, E. F., Mello, V. C., & Báo, S. N. (2023) · Molecules · doi:10.3390/molecules28227653 · Cited by 83
“This is also true for nanocarriers [59].”
Tariq, U., Gupta, M., Pathak, S., Patil, R., Dohare, A., & Misra, S. K. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00454 · Cited by 75
Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery
Hamadani, C. M., Dasanayake, G. S., Gorniak, M. E., Pride, M. C., Monroe, W. G., Chism, C. M., Heintz, R., Jarrett, E., Singh, G., Edgecomb, S. X., et al. (2023) · Nature Protocols · doi:10.1038/s41596-023-00843-6 · Cited by 71
Zwitterionic hydrogel for sustained release of growth factors to enhance wound healing
Xiao, Z., Zheng, X., An, Y., Wang, K., Zhang, J., He, H., & Wu, J. (2020) · Biomaterials Science · doi:10.1039/d0bm01608j · Cited by 70
Krupka, O., & Hudhomme, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076308 · Cited by 68
Construction and application of adenoviral vectors
Zhang, H., Wang, H., An, Y., & Chen, Z. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.09.004 · Cited by 75
Jayakumar, S., Saravanan, T., & Philip, J. (2023) · Hybrid Advances · doi:10.1016/j.hybadv.2023.100100 · Cited by 72
Liu, X., Jansman, M. M. T., & Hosta‐Rigau, L. (2020) · Biomaterials Science · doi:10.1039/d0bm01118e · Cited by 65
Chen, B., Zhao, Y., Zhang, Y., Pan, Y.-J., Xia, H., Kankala, R. K., Wang, S., Liu, G., & Chen, A. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.07.023 · Cited by 84
“Compared to solely positively or negatively charged polymers that are easier to be eliminated by the reticuloendothelial system (RES), zwitterionic polymers possessing either zwitterionic groups or a mixture of anionic and cationic terminal groups have demonstrated high resistance to non-specific protein binding, ther…”
BackgroundEmon, D. D., Islam, M. S., Mazumder, M. A. R., Aziz, M. G., & Rahman, M. S. (2025) · Food Chemistry Advances · doi:10.1016/j.focha.2025.100923 · Cited by 80
Anwar, S., Mir, F., & Yokota, T. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041130 · Cited by 71
Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
Neary, M. T., Mulder, L. M., Kowalski, P. S., MacLoughlin, R. J., Crean, A. M., & Ryan, K. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.012 · Cited by 70
Breaking biological barriers: Engineering polymeric nanoparticles for cancer therapy
Austria, E. S., Jr., Bilek, M., Varamini, P., & Akhavan, B. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102552 · Cited by 66
PEGylation technology: addressing concerns, moving forward
Simberg, D., Barenholz, Y., Roffler, S. R., Landfester, K., Kabanov, A. V., & Moghimi, S. M. (2025) · Drug Delivery · doi:10.1080/10717544.2025.2494775 · Cited by 67
“…such as tagging drug carriers (or proteins) to albumin, Fc fragments, polysarcosine, polyglycerol derivatives, polyvinylpyrrolidone and polyoxazolines has been proposed (Yang et al. 2016; Hoang Thi et al. 2020; Berger et al. 2023; Gao et al. 2024; Kang et al. 2024; Lorson et al. 2018).”
Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes
Trac, N. T., & Chung, E. J. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211010762 · Cited by 63
Maleimide-Decorated PEGylated Mucoadhesive Liposomes for Ocular Drug Delivery
Moiseev, R. V., Kaldybekov, D. B., Filippov, S. K., Rădulescu, A., & Khutoryanskiy, V. V. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c02086 · Cited by 66
Stealth nanorods via the aqueous living crystallisation-driven self-assembly of poly(2-oxazoline)s
Finnegan, J. R., Pilkington, E. H., Alt, K., Rahim, M. A., Kent, S. J., Davis, T. P., & Kempe, K. (2021) · Chemical Science · doi:10.1039/d1sc00938a · Cited by 63
Self-citationHybrid core-shell particles for mRNA systemic delivery
Andretto, V., Repellin, M., Pujol, M., Almouazen, E., Sidi‐Boumedine, J., Granjon, T., Zhang, H., Remaut, K., Jordheim, L. P., Briançon, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.042 · Cited by 55
Phytochemical-Based Nanomaterials against Antibiotic-Resistant Bacteria: An Updated Review
Díaz‐Puertas, R., Álvarez‐Martínez, F. J., Falcó, A., Barrajón‐Catalán, E., & Mallavia, R. M. (2023) · Polymers · doi:10.3390/polym15061392 · Cited by 68
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.